Publication | Closed Access

Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma

5-Fluorouracil Plus LeucovorinGastrointestinal OncologyMedicineCancer ManagementPharmacologyClinical TrialsColorectal CancerPhase Iii TrialMedical Resource UsePharmacotherapyCancer TreatmentOncology